Chemed (CHE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Chemed (CHE) reported $564.53 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 7.2%. EPS of $5.32 for the same period compares to $4.74 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $560.1 million, representing a surprise of +0.79%. The company delivered an EPS surprise of +8.13%, with the consensus EPS estimate being $4.92.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Chemed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Average daily census (ADC) - Total: 18,859 compared to the 18,684 average estimate based on two analysts.
Number of days in relevant time period: 92 Days versus 92 Days estimated by two analysts on average.
Days of care - Total: 1,735,018 versus 1,718,969 estimated by two analysts on average.
Net Revenue- Medicare cap allowance: -$0.13 million versus the two-analyst average estimate of -$2.77 million. The reported number represents a year-over-year change of -79.8%.
Service revenues and sales- Roto-Rooter: $230.80 million versus the two-analyst average estimate of $228.68 million. The reported number represents a year-over-year change of +0.4%.
Service revenues and sales- VITAS: $333.73 million compared to the $331.42 million average estimate based on two analysts. The reported number represents a change of +12.5% year over year.
Adjusted EBITDA- Roto-Rooter: $66.94 million versus $64.28 million estimated by two analysts on average.
View all Key Company Metrics for Chemed here>>>
Shares of Chemed have returned -1.3% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Chemed Corporation (CHE) : Free Stock Analysis Report
